Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGB-9768 in Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT07796256Phase 2Not yet recruiting
- Sponsor
- SanegeneBio
- Start
- Oct 2026
- Primary completion
- Aug 2027
- Countries
- 1
01
Overview
A Phase 2 trial of SGB-9768 in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by SanegeneBio. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
SGB-9768
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT07796256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07796256.